Company Overview
About Lilly (Eli)
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.
Business Model & Competitive Advantage
Eli Lilly's pharmaceutical innovation model creates competitive advantages through the tirzepatide franchise's superior clinical profile and pipeline depth across multiple GLP-1-adjacent mechanisms: while Novo Nordisk dominates the injectable semaglutide segment (Ozempic for diabetes, Wegovy for obesity), Lilly's tirzepatide delivered higher weight loss in head-to-head comparisons and secured additional indications (obstructive sleep apnea, heart failure with obesity — both FDA-approved in 2024) that create clinical differentiation beyond simple metabolic weight loss. The orforglipron program (oral GLP-1 receptor agonist pill, phase 3 trials showing 7-8% HbA1c reduction and 10% weight loss) represents the next clinical catalyst — an oral obesity treatment that eliminates the weekly injection barrier could dramatically expand the treatable population beyond the patients who self-inject semaglutide or tirzepatide. Lilly's oncology pipeline (Verzenio/abemaciclib for HR+ breast cancer, $4.2B revenue, growing as MONARCH trials expand indications) and immunology pipeline (mirikizumab for ulcerative colitis and Crohn's disease, lebrikizumab for atopic dermatitis) provide earnings diversification beyond the GLP-1 franchise.
Competitive Landscape 2025–2026
In 2025, Eli Lilly competes in GLP-1 diabetes/obesity therapeutics, oncology, and immunology against Novo Nordisk (CPH: NOVO B, Ozempic and Wegovy semaglutide, global GLP-1 leader by market share), AstraZeneca (LON: AZN, oncology and cardiovascular), and Pfizer (NYSE: PFE, oncology and vaccines) for diabetes and obesity drug market share, oncology IO and CDK4/6 inhibitor competition, and global pharmaceutical distribution. The supply constraint environment for tirzepatide (FDA shortage designation for Zepbound and Mounjaro through most of 2024) has eased as Lilly's manufacturing expansion comes online — new capacity from Lilly's $18B manufacturing investment reduces supply shortages that limited revenue growth in 2024 below demand levels. The orforglipron oral GLP-1 Phase 3 data (expected late 2025/2026) represents the defining competitive event for the obesity treatment market: an effective oral pill would capture patients who refuse injections and expand the treatable obesity population by hundreds of millions globally. The 2025 strategy focuses on tirzepatide supply expansion (filling unmet demand as manufacturing capacity increases), oral GLP-1 clinical program advancement, and Verzenio breast cancer market share growth against CDK4/6 competitors Pfizer's Ibrance and Novartis's Kisqali.
The Lilly (Eli) Story
Founders
Company Timeline
Major milestones in Lilly (Eli)'s journey
Leadership Team
Meet the leaders behind Lilly (Eli)
David A. Ricks
David A. Ricks became CEO in January 2017 and was elected chair of the board in June 2017. He joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into international leadership positions. Under his leadership, Lilly achieved $1 trillion market cap and record revenue growth.
Lucas Montarce
Lucas Montarce was appointed CFO in September 2024, bringing extensive finance leadership experience. Since joining Lilly in 2001, he served as group VP and corporate controller, CFO of Lilly Research Laboratories, CFO of Lilly International, and CFO of Elanco Health. He holds an MBA from CEMA and a bachelor's in business accounting from Catholic University of Argentina.
Daniel M. Skovronsky, MD, PhD
Dr. Skovronsky is chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology, with responsibility for global business development. He joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals, where he had been CEO since founding it in 2004. He has led breakthrough research in Alzheimer's disease and other therapeutic areas.
Anat Hakim
Anat Hakim serves as executive vice president, general counsel and secretary of Eli Lilly and Company, overseeing all legal affairs, corporate governance, compliance, and regulatory matters for the global pharmaceutical enterprise.
Former CFO: Anat Ashkenazi
Anat Ashkenazi served as CFO from 2021 to July 2024, during which Lilly's market cap tripled. She joined Lilly in 2001 and held roles across strategy, finance, and Six Sigma, including CFO positions for Oncology, Diabetes, Global Manufacturing & Quality, and R&D. She left to become CFO of Alphabet/Google in 2024.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Lilly (Eli) is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $45100M in revenue, Lilly (Eli) operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Lilly (Eli) with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Lilly (Eli)? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Lilly (Eli) Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Lilly (Eli) vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →